On Thursday, Harmony Biosciences reached an important technical benchmark, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 81, up from 78 the day before.
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
History shows that the top-performing stocks typically have an 80 or higher RS Rating as they begin their biggest price moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Harmony Biosciences is building a cup with handle with a 40.93 entry. See if it can clear the breakout price in heavy volume.
Harmony Biosciences posted 6% earnings growth in the latest quarterly report. Sales gains came in at 16%. The company is expected to report its latest earnings and sales numbers on or around Feb. 19.
Harmony Biosciences holds the No. 4 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals is the No. 1-ranked stock within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
